BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Mitsubishi Tanabe Pharma sales and marketing update

Mitsubishi Tanabe launched Telavic telaprevir in Japan to treat chronic HCV infection in Japan. Mitsubishi Tanabe has rights to the small molecule HCV NS3 protease inhibitor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX Cambridge, Mass.)...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >